RGNX – REGENXBIO Inc.
Float Short %
10.28
Margin Of Safety %
Put/Call OI Ratio
0.84
EPS Next Q Diff
-0.19
EPS Last/This Y
1.33
EPS This/Next Y
1.39
Price
13.16
Target Price
31.25
Analyst Recom
1.42
Performance Q
38.82
Relative Volume
0.96
Beta
1.08
Ticker: RGNX
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-11-10 | RGNX | 11.03 | 0.71 | 0.11 | 4438 |
| 2025-11-11 | RGNX | 11.56 | 0.72 | 0.00 | 4432 |
| 2025-11-12 | RGNX | 11.6 | 0.71 | 0.02 | 4445 |
| 2025-11-13 | RGNX | 11.66 | 0.70 | 0.09 | 4503 |
| 2025-11-14 | RGNX | 11.51 | 0.70 | 0.02 | 4492 |
| 2025-11-17 | RGNX | 11.14 | 0.70 | 0.03 | 4490 |
| 2025-11-18 | RGNX | 11.24 | 0.69 | 5.14 | 4536 |
| 2025-11-19 | RGNX | 10.94 | 0.68 | 6.00 | 4506 |
| 2025-11-20 | RGNX | 10.85 | 0.70 | 0.00 | 4561 |
| 2025-11-21 | RGNX | 11.78 | 0.70 | 0.25 | 4574 |
| 2025-11-24 | RGNX | 12.23 | 0.80 | 0.10 | 3789 |
| 2025-11-25 | RGNX | 13.47 | 0.79 | 0.00 | 3816 |
| 2025-11-26 | RGNX | 13.26 | 0.78 | 1.75 | 3863 |
| 2025-12-01 | RGNX | 12.62 | 0.84 | 0.02 | 4245 |
| 2025-12-02 | RGNX | 12.22 | 0.84 | 0.00 | 4252 |
| 2025-12-03 | RGNX | 12.9 | 0.83 | 0.67 | 4259 |
| 2025-12-04 | RGNX | 12.98 | 0.83 | 1.30 | 4261 |
| 2025-12-05 | RGNX | 13.16 | 0.84 | 0.40 | 4304 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-11-10 | RGNX | 11.02 | 117.0 | 239.3 | -2.28 |
| 2025-11-11 | RGNX | 11.55 | 117.0 | 250.1 | -3.20 |
| 2025-11-12 | RGNX | 11.60 | 117.0 | 242.9 | -3.20 |
| 2025-11-13 | RGNX | 11.64 | 117.0 | 242.8 | -3.20 |
| 2025-11-14 | RGNX | 11.52 | 26.3 | 240.7 | -3.20 |
| 2025-11-17 | RGNX | 11.14 | 26.7 | 237.1 | -3.20 |
| 2025-11-18 | RGNX | 11.24 | 26.7 | 243.6 | -3.20 |
| 2025-11-19 | RGNX | 10.93 | 26.7 | 237.5 | -3.20 |
| 2025-11-20 | RGNX | 10.85 | 26.7 | 241.1 | -3.20 |
| 2025-11-21 | RGNX | 11.81 | 26.7 | 256.9 | -3.20 |
| 2025-11-24 | RGNX | 12.24 | 26.7 | 248.1 | -3.20 |
| 2025-11-25 | RGNX | 13.45 | 26.7 | 258.0 | -3.26 |
| 2025-11-26 | RGNX | 13.26 | 26.7 | 240.1 | -3.26 |
| 2025-12-01 | RGNX | 12.60 | 21.1 | 233.4 | -3.26 |
| 2025-12-02 | RGNX | 12.21 | 21.1 | 237.4 | -3.26 |
| 2025-12-03 | RGNX | 12.88 | 21.1 | 250.8 | -3.26 |
| 2025-12-04 | RGNX | 12.98 | 21.1 | 243.6 | -3.26 |
| 2025-12-05 | RGNX | 13.16 | 21.1 | 244.5 | -3.26 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-11-10 | RGNX | -1.29 | -2.26 | 10.55 |
| 2025-11-11 | RGNX | -1.29 | -2.26 | 10.55 |
| 2025-11-12 | RGNX | -1.29 | -2.26 | 9.83 |
| 2025-11-13 | RGNX | -1.29 | -2.26 | 9.83 |
| 2025-11-14 | RGNX | -1.29 | -2.26 | 9.81 |
| 2025-11-17 | RGNX | -0.84 | -1.83 | 9.86 |
| 2025-11-18 | RGNX | -0.80 | -1.83 | 9.86 |
| 2025-11-19 | RGNX | -0.80 | -1.83 | 9.86 |
| 2025-11-20 | RGNX | -0.80 | -1.83 | 9.86 |
| 2025-11-21 | RGNX | -0.80 | -1.83 | 9.86 |
| 2025-11-24 | RGNX | -0.80 | -0.76 | 9.86 |
| 2025-11-25 | RGNX | -0.80 | -0.76 | 9.86 |
| 2025-11-26 | RGNX | -0.80 | -0.76 | 10.28 |
| 2025-12-01 | RGNX | -0.80 | -1.21 | 10.28 |
| 2025-12-02 | RGNX | -0.80 | -1.21 | 10.28 |
| 2025-12-03 | RGNX | -0.80 | -1.21 | 10.28 |
| 2025-12-04 | RGNX | -0.80 | -1.21 | 10.28 |
| 2025-12-05 | RGNX | -0.80 | -1.21 | 10.28 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.2
Avg. EPS Est. Current Quarter
-0.8
Avg. EPS Est. Next Quarter
-1.39
Insider Transactions
-0.8
Institutional Transactions
-1.21
Beta
1.08
Average Sales Estimate Current Quarter
61
Average Sales Estimate Next Quarter
77
Fair Value
Quality Score
39
Growth Score
40
Sentiment Score
68
Actual DrawDown %
73.8
Max Drawdown 5-Year %
-89.4
Target Price
31.25
P/E
Forward P/E
PEG
P/S
4.13
P/B
4.13
P/Free Cash Flow
EPS
-3.49
Average EPS Est. Cur. Y
-3.26
EPS Next Y. (Est.)
-1.87
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-110.29
Relative Volume
0.96
Return on Equity vs Sector %
-137.1
Return on Equity vs Industry %
-122.2
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
-0.98
EBIT Estimation
244.5
REGENXBIO Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 353
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
stock quote shares RGNX – REGENXBIO Inc. Stock Price stock today
news today RGNX – REGENXBIO Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RGNX – REGENXBIO Inc. yahoo finance google finance
stock history RGNX – REGENXBIO Inc. invest stock market
stock prices RGNX premarket after hours
ticker RGNX fair value insiders trading